Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

Blood (2011) 118 (21): 3706.

https://doi.org/10.1182/blood.V118.21.3706.3706

Published: 2011

Journal Articles

FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma

Natalina E. Elliott, Susan M. Cleveland, Victor Grann, John Janik, Thomas A. Waldmann, Utpal P. Davé

Blood (2011) 118 (14): 3911–3921.

https://doi.org/10.1182/blood-2010-12-319467

Published: 2011

Includes: Supplemental data

Journal Articles

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients.

Kieron Dunleavy, MD, Stefania Pittaluga, MD, John Janik, MD, Nicole Grant, MPH, Margaret Shovlin, RN, Seth Steinberg, PhD, Mark Raffeld, MD, Louis Staudt, MD, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 209.

https://doi.org/10.1182/blood.V108.11.209.209

Published: 2006

Journal Articles

DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.

Wyndham H. Wilson, MD, PhD, Kieron Dunleavy, MD, Stefania Pittaluga, MD, Nicole Grant, MPH, Margaret Shovlin, RN, Seth Steinberg, PhD, Mark Raffeld, MD, Louis Staudt, MD, PhD, Elaine S. Jaffe, MD, John Janik, MD

Blood (2006) 108 (11): 206.

https://doi.org/10.1182/blood.V108.11.206.206

Published: 2006

Journal Articles

Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.

Kieron Dunleavy, MD, Stefania Pittaluga, MD, John Janik, MD, Nicole Grant, MPH, Margaret Shovlin, RN, Richard Little, MD, Robert Yarchoan, MD, Seth Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 2736.

https://doi.org/10.1182/blood.V108.11.2736.2736

Published: 2006

Journal Articles

Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).

Kieron Dunleavy, MD, Alan S. Wayne, MD, Richard Little, MD, Nicole Grant, MPH, Seth Steinberg, PhD, Elaine S. Jaffe, MD, Stefania Pittaluga, MD, Robert Yarchoan, MD, Jorge Carrasquillo, MD, John Janik, MD, Wyndham H. Wilson, MD, PhD

Blood (2006) 108 (11): 2740.

https://doi.org/10.1182/blood.V108.11.2740.2740

Published: 2006

Journal Articles

Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors

Meili Zhang, Zhengsheng Yao, Zhuo Zhang, Kayhan Garmestani, Carolyn K. Goldman, Jeffrey V. Ravetch, John Janik, Martin W. Brechbiel, Thomas A. Waldmann

Blood (2006) 108 (2): 705–710.

https://doi.org/10.1182/blood-2005-11-4607

Published: 2006

Journal Articles

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation.

Kieron Dunleavy, MD, Stefania Pittaluga, MD, John Janik, MD, Nicole Grant, RN, Seth Steinberg, PhD, Louis Staudt, MD, PhD, Elaine Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2005) 106 (11): 929.

https://doi.org/10.1182/blood.V106.11.929.929

Published: 2005

Journal Articles

The Addition of Rituximab to Dose-Adjusted EPOCH with HAART Suspension Is Highly Effective and Tolerable in AIDS-Related Lymphoma (ARL) and Allows the Delivery of Abbreviated Chemotherapy.

Kieron Dunleavy, MD, Alan Wayne, M.D, Richard Little, M.D, Nicole Grant, M.P.H., Seth Steinberg, Ph.D, Elaine S. Jaffe, MD, Stefania Pittaluga, MD, Robert Yarchoan, MD, Jorge Carrasquillo, MD, John Janik, MD, Wyndham H. Wilson, MD, PhD

Blood (2005) 106 (11): 930.

https://doi.org/10.1182/blood.V106.11.930.930

Published: 2005

Journal Articles

Combination therapy for adult T-cell leukemia–xenografted mice: flavopiridol and anti-CD25 monoclonal antibody

Meili Zhang, Zhuo Zhang, Carolyn K. Goldman, John Janik, Thomas A. Waldmann

Blood (2005) 105 (3): 1231–1236.

https://doi.org/10.1182/blood-2004-05-1709

Published: 2005

Journal Articles

Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL).

Kieron Dunleavy, M.D., Richard Little, M.D., Juan Gea-Banacloche, M.D., Nicole Grant, M.P.H., Seth Steinberg, Ph.D., Robert Yarchoan, M.D., Stefania Pittaluga, M.D., Elaine Jaffe, M.D., John Janik, M.D., Wyndham H. Wilson, M.D., Ph.D.

Blood (2004) 104 (11): 3111.

https://doi.org/10.1182/blood.V104.11.3111.3111

Published: 2004

Journal Articles

Phase I/II study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma.

Kieron Dunleavy, M.D., John Janik, M.D., Juan Gea-Banacloche, M.D., Margaret Shovlin, B.S.N., Therese White, M.S.N., Neta Goldschmidt, M.D., Nicole Grant, M.P.H., Omer Koc, M.D., Stefania Pittaluga, M.D., Elaine Jaffe, M.D., Louis Staudt, M.D., Ph.D., Wyndham H. Wilson, M.D., Ph.D.

Blood (2004) 104 (11): 1385.

https://doi.org/10.1182/blood.V104.11.1385.1385

Published: 2004

Journal Articles

Dose-Adjusted EPOCH-Rituximab Is Highly Effective in the GCB and ABC Subtypes of Untreated Diffuse Large B-Cell Lymphoma.

Wyndham H. Wilson, M.D., Ph.D., Kieron Dunleavy, M.D., Stefania Pittaluga, M.D., Nicole Grant, M.P.H., Seth Steinberg, Ph.D., Mark Raffeld, M.D., Bruce Chabner, M.D., Michael Grossbard, M.D., Elaine Jaffe, M.D., Louis Staudt, M.D., Ph.D., John Janik, M.D.

Blood (2004) 104 (11): 159.

https://doi.org/10.1182/blood.V104.11.159.159

Published: 2004

Journal Articles

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy

Wyndham H. Wilson, Michael L. Grossbard, Stefania Pittaluga, Diane Cole, Deborah Pearson, Nicole Drbohlav, Seth M. Steinberg, Richard F. Little, John Janik, Martin Gutierrez, Mark Raffeld, Louis Staudt, Bruce D. Cheson, Dan L. Longo, Nancy Harris, Elaine S. Jaffe, Bruce A. Chabner, Robert Wittes, Frank Balis

Blood (2002) 99 (8): 2685–2693.

https://doi.org/10.1182/blood.V99.8.2685

Published: 2002

NARROW

Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients.

DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.

Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.

Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).

Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors

Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation.

The Addition of Rituximab to Dose-Adjusted EPOCH with HAART Suspension Is Highly Effective and Tolerable in AIDS-Related Lymphoma (ARL) and Allows the Delivery of Abbreviated Chemotherapy.

Combination therapy for adult T-cell leukemia–xenografted mice: flavopiridol and anti-CD25 monoclonal antibody

Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL).

Phase I/II study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma.

Dose-Adjusted EPOCH-Rituximab Is Highly Effective in the GCB and ABC Subtypes of Untreated Diffuse Large B-Cell Lymphoma.

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only